Analyst Activity – Credit Suisse Group Raises Its Price Target On Alnylam Pharmaceuticals (NASDAQ:ALNY) to $154.00

Analyst Ratings For Alnylam Pharmaceuticals (NASDAQ:ALNY)

Today, Credit Suisse Group raised its price target on Alnylam Pharmaceuticals (NASDAQ:ALNY) to $154.00 per share.

Some recent analyst ratings include

    Recent Insider Trading Activity For Alnylam Pharmaceuticals (NASDAQ:ALNY)
    Alnylam Pharmaceuticals (NASDAQ:ALNY) has insider ownership of 4.30% and institutional ownership of 92.44%.

    • On 1/4/2018 Michael Mason, VP, sold 36,745 with an average share price of $131.59 per share and the total transaction amounting to $4,835,274.55.
    • On 12/20/2017 Laurie Keating, SVP, sold 6,249 with an average share price of $121.20 per share and the total transaction amounting to $757,378.80.
    • On 12/1/2017 Laurie Keating, SVP, sold 30,000 with an average share price of $135.89 per share and the total transaction amounting to $4,076,700.00.
    • On 11/22/2017 John Maraganore, CEO, sold 73,415 with an average share price of $130.90 per share and the total transaction amounting to $9,610,023.50.
    • On 11/15/2017 John Maraganore, CEO, sold 74,000 with an average share price of $126.86 per share and the total transaction amounting to $9,387,640.00.
    • On 11/2/2017 Dennis A Ausiello, Director, sold 20,000 with an average share price of $130.00 per share and the total transaction amounting to $2,600,000.00.
    • On 10/30/2017 Akshay Vaishnaw, EVP, sold 33,666 with an average share price of $121.46 per share and the total transaction amounting to $4,089,072.36.

    Recent Trading Activity for Alnylam Pharmaceuticals (NASDAQ:ALNY)
    Shares of Alnylam Pharmaceuticals closed the previous trading session at with 132367 shares trading hands.

    An ad to help with our costs